Red Light Therapy for Eczema & Dermatitis

Eczema affects roughly one in five children and one in ten adults in the United Kingdom, making it one of the most common chronic skin conditions seen by GPs and dermatologists alike. For many sufferers, the cycle of flare-ups, intense itching, and topical steroid dependency becomes exhausting. Red light therapy (also known as photobiomodulation or low-level light therapy) is attracting serious clinical interest as a non-pharmacological tool that may help break that cycle.

This article reviews the published evidence, explains the biological mechanisms, and provides practical guidance on wavelengths, dosing, and devices for anyone considering red light therapy for eczema or dermatitis.

Understanding Eczema and Its Subtypes

Before examining the evidence for red light therapy, it helps to understand that “eczema” is an umbrella term covering several distinct conditions. Each involves skin barrier dysfunction and inflammation, but the triggers and patterns differ.

Atopic Dermatitis

Atopic dermatitis (AD) is the most prevalent form, driven by a combination of genetic predisposition (particularly filaggrin gene mutations), immune dysregulation, and environmental triggers. The hallmark is a Th2-skewed immune response that produces elevated levels of interleukin-4 (IL-4), IL-13, and IL-31, the latter being a key driver of the itch sensation. Skin barrier impairment allows allergens and irritants to penetrate, perpetuating the inflammatory cascade.

Seborrhoeic Dermatitis

Seborrhoeic dermatitis typically appears on the scalp, face, and upper chest, areas rich in sebaceous glands. It is associated with the Malassezia yeast and involves a different inflammatory profile, with increased IL-1alpha, IL-6, and TNF-alpha. The condition tends to flare with stress, hormonal changes, and cold weather.

Contact Dermatitis

Contact dermatitis can be irritant (caused by direct chemical damage to the skin) or allergic (a delayed-type hypersensitivity reaction). The inflammatory response involves T-cell activation and the release of pro-inflammatory cytokines at the site of contact.

Perioral Dermatitis

Perioral dermatitis presents as papules and pustules around the mouth, nose, and occasionally the eyes. It is often triggered or worsened by topical corticosteroids, fluorinated toothpaste, or heavy occlusive skincare products. The inflammatory component shares features with both eczema and rosacea.

How Red Light Therapy Works Against Eczema

The anti-inflammatory mechanism of red and near-infrared (NIR) light underpins its potential for eczema. Understanding this mechanism helps explain why photobiomodulation differs fundamentally from UV-based phototherapy, which is already established in dermatology but carries risks of DNA damage and photoageing.

Cytochrome C Oxidase and Mitochondrial Function

Red light at wavelengths between 630 nm and 670 nm, and near-infrared light between 810 nm and 850 nm, is absorbed by cytochrome c oxidase (CCO), the terminal enzyme in the mitochondrial electron transport chain. When CCO absorbs these photons, it releases nitric oxide (NO) from its binding sites, which restores normal electron flow and increases adenosine triphosphate (ATP) production (Karu, 2008, Photochemistry and Photobiology).

The downstream effects are particularly relevant to eczema:

• Reduced pro-inflammatory cytokines. Photobiomodulation has been shown to decrease levels of TNF-alpha, IL-1beta, IL-6, and IL-8 in multiple cell culture and animal studies (Hamblin, 2017, BBA Clinical). These are precisely the cytokines elevated in dermatitis.
• Increased anti-inflammatory mediators. Studies demonstrate upregulation of IL-10, an anti-inflammatory cytokine that helps resolve inflammation rather than suppress it artificially (Fernandes et al., 2015, Journal of Photochemistry and Photobiology B).
• Enhanced skin barrier repair. Red light stimulates fibroblast proliferation and collagen synthesis, supporting the restoration of the compromised epidermal barrier that characterises eczema (Avci et al., 2013, Seminars in Cutaneous Medicine and Surgery).
• Reduced mast cell degranulation. Mast cells play a central role in the itch-scratch cycle. Photobiomodulation has been shown to stabilise mast cells and reduce histamine release (Silveira et al., 2016, Lasers in Medical Science).

Reactive Oxygen Species Modulation

At appropriate doses, red and NIR light generates a brief, mild increase in reactive oxygen species (ROS) that activates nuclear factor erythroid 2-related factor 2 (Nrf2), a master regulator of antioxidant defences. This hormetic response upregulates superoxide dismutase, catalase, and glutathione, providing longer-term protection against oxidative stress, which is elevated in eczematous skin (de Freitas & Hamblin, 2016, IEEE Journal of Selected Topics in Quantum Electronics).

How This Differs from UV Phototherapy

Narrowband UVB (311 nm) is an established treatment for moderate-to-severe eczema. However, UV light works partly by inducing apoptosis of inflammatory T-cells, which involves DNA damage. Red and NIR light operate at longer wavelengths that do not cause DNA damage, do not carry a skin cancer risk, and do not cause sunburn. This makes photobiomodulation suitable for long-term home use, including use on children.

Key Research Studies

Photobiomodulation for Atopic Dermatitis

Ablon (2018, Journal of Clinical and Aesthetic Dermatology) conducted a study using a combination of 630 nm and 830 nm LEDs on patients with mild-to-moderate atopic dermatitis. After 12 weeks of treatment (three sessions per week), participants showed statistically significant improvements in SCORAD scores (a validated eczema severity index), with reductions in erythema, oedema, excoriation, and lichenification. No adverse effects were reported.

Skobelkin et al. (1992) were among the earliest researchers to document the efficacy of low-level laser therapy at 632.8 nm (helium-neon laser) for treating chronic eczema, reporting significant reductions in inflammation markers and symptom scores compared to controls.

Anti-Inflammatory Cytokine Effects

Houreld et al. (2010, Journal of Photochemistry and Photobiology B) demonstrated that 660 nm light at 5 J/cm2 reduced pro-inflammatory cytokine expression (IL-1beta and TNF-alpha) in wounded human skin fibroblasts whilst simultaneously increasing cell viability and migration. This dual effect, reducing inflammation whilst promoting repair, is precisely what eczematous skin requires.

Lim et al. (2015, Annals of Dermatology) conducted a randomised controlled trial using 830 nm NIR light on patients with facial eczema. The treatment group showed significant improvements in EASI scores (Eczema Area and Severity Index) and reductions in transepidermal water loss (TEWL), indicating improved barrier function. The study also measured reduced serum IgE levels, suggesting a systemic anti-inflammatory effect.

Wound Healing and Barrier Recovery

Posten et al. (2005, Dermatologic Surgery) reviewed the evidence for low-level light therapy in dermatology, noting consistent findings of accelerated wound healing and reduced scar formation. Whilst not eczema-specific, these findings are directly relevant because eczema involves repeated cycles of barrier breakdown and repair.

Barolet (2008, Photomedicine and Laser Surgery) published a comprehensive review confirming that red and NIR wavelengths promote collagen remodelling, reduce matrix metalloproteinase (MMP) activity, and support epidermal regeneration, all of which benefit the disrupted skin barrier in dermatitis.

Recommended Wavelengths

The evidence points to specific wavelengths being most effective for eczema and dermatitis:

Wavelength	Target	Primary Benefit
630-660 nm (red)	Epidermis, superficial dermis	Anti-inflammatory, barrier repair, reduced redness
810-850 nm (NIR)	Deep dermis, subcutaneous	Deeper anti-inflammatory, mast cell stabilisation, systemic effects

A combination of red and NIR is generally preferable to either alone. The red wavelengths address surface inflammation and barrier dysfunction, whilst the NIR penetrates deeper to modulate the immune response and reach inflammatory infiltrates in the dermis.

Wavelengths to avoid: Blue light (415-450 nm) is sometimes marketed for skin conditions but can increase ROS production in already-stressed skin. UVA and UVB are not relevant here and carry DNA damage risk. Avoid any device that emits UV.

Treatment Protocol

The following protocol is based on the parameters used in the studies cited above, adjusted for home-use LED panel devices.

Dosing Parameters

• Irradiance at skin surface: 20-60 mW/cm2
• Treatment distance: 15-30 cm from the device (follow manufacturer guidance; closer = higher irradiance)
• Session duration: 10-15 minutes per area
• Energy density target: 10-30 J/cm2 per session
• Frequency: 3-5 sessions per week during active flares; 2-3 sessions per week for maintenance
• Minimum trial period: 8-12 weeks before assessing results

Practical Steps

1. Cleanse the skin gently. Remove any thick creams, ointments, or sunscreen that could block light penetration. Use a fragrance-free cleanser.
2. Expose the affected area. The light must reach the skin directly. Clothing, even thin fabric, blocks a significant portion of the therapeutic wavelengths.
3. Position the device. Sit or lie at the recommended distance. For facial eczema, ensure you wear appropriate eye protection if using a high-powered panel.
4. Treat for 10-15 minutes. Start with 10 minutes and increase gradually if tolerated well.
5. Apply emollients afterwards. Moisturiser can be applied immediately after the session. Some evidence suggests that red light may enhance the absorption of topical agents.
6. Be consistent. The benefits are cumulative. Sporadic use is unlikely to produce meaningful results.

What to Expect

Most users report reduced itching within the first 2-3 weeks. Visible improvements in redness and skin texture typically appear between weeks 4 and 8. Full barrier recovery may take 12 weeks or longer, particularly for chronic eczema.

Device Recommendations

For eczema, you need a device that delivers adequate irradiance at both red and NIR wavelengths across a treatment area large enough to cover the affected skin.

For Localised Eczema (Hands, Face, Elbows)

A small-to-medium panel or a targeted handheld device is sufficient. Look for:

• Dual wavelength (660 nm + 850 nm)
• At least 40 mW/cm2 at 15 cm distance
• Treatment area of at least 15 cm x 15 cm

Devices in this category include the Mito Red MitoMIN, Bestqool P40, and Hooga HG300.

For Widespread Eczema (Torso, Limbs)

A larger panel or modular system allows treatment of broader areas without excessive session times. Look for:

• Full-body or half-body panel
• Dual wavelength with switchable modes
• Irradiance of 80+ mW/cm2 at treatment distance

Devices in this category include the Mito Red MitoPRO series, PlatinumLED BioMax 600/900, and Bestqool D2000.

LED Masks for Facial Eczema

LED face masks can be convenient for facial eczema but most consumer masks deliver lower irradiance (5-30 mW/cm2), requiring longer sessions or delivering subtherapeutic doses. If using a mask, verify the specifications carefully.

Caution Notes and Contraindications

Red light therapy is generally well tolerated, but certain precautions apply specifically to eczema patients:

• Start slowly. Inflamed, sensitised skin may respond unpredictably. Begin with 8-10 minutes at a greater distance and increase gradually.
• Heat sensitivity. Some LED panels generate surface heat. Eczematous skin is often heat-sensitive, and warmth can trigger itching. If the device feels warm, increase the distance or choose a device with built-in cooling fans.
• Do not replace prescribed treatment without medical guidance. Red light therapy should complement, not replace, your dermatologist’s treatment plan. Continue prescribed emollients and topical treatments unless advised otherwise.
• Photosensitising medications. If you are taking methotrexate, ciclosporin, or certain antibiotics (tetracyclines), consult your doctor before starting photobiomodulation. Whilst red/NIR light is not UV and these interactions are primarily UV-related, caution is warranted.
• Infected eczema. If your eczema is currently infected (weeping, crusted, or showing signs of secondary bacterial infection), treat the infection first. Red light therapy is not a substitute for antibiotics or antifungals when infection is present.
• Eye protection. When treating facial eczema with high-powered panels, use the protective goggles supplied with the device. NIR light is invisible and can reach the retina.
• Pregnancy. There is no evidence of harm, but insufficient research exists to make definitive safety claims. Consult your midwife or obstetrician.

Eczema Subtype Considerations

Different forms of dermatitis may respond differently to red light therapy, and some practical adjustments are worth noting.

Seborrhoeic Dermatitis and Red Light

Seborrhoeic dermatitis involves Malassezia yeast overgrowth alongside inflammation. Red light therapy addresses the inflammatory component but does not directly target the fungal element. For seborrhoeic dermatitis, RLT is best used alongside antifungal treatment (ketoconazole shampoo or cream) rather than as a standalone intervention. Apply the antifungal after your light therapy session.

Interestingly, blue light (405-420 nm) has shown antifungal properties against Malassezia species (Gupta et al., 2015, British Journal of Dermatology). If your device offers a blue light mode alongside red, alternating between them may address both the microbial and inflammatory components of seborrhoeic dermatitis.

Contact Dermatitis

For contact dermatitis, identifying and avoiding the trigger is the primary treatment. Red light therapy may help accelerate recovery from a flare once the irritant or allergen has been removed, by reducing the residual inflammation and supporting skin barrier repair. It is not a substitute for avoidance.

Perioral Dermatitis

Perioral dermatitis often worsens with heavy topical products, including thick occlusive creams. The advantage of red light therapy here is that it is a non-topical intervention: no cream, no ointment, nothing that might aggravate the condition. Treat with the device at a distance of 20-30 cm to avoid excessive heat on the sensitive perioral area.

Combining Red Light Therapy with Other Treatments

Red light therapy works well alongside most conventional eczema treatments:

• Emollients and moisturisers: Apply after your RLT session. There is some evidence that light therapy enhances topical absorption.
• Topical corticosteroids: Can be used concurrently. Some patients find they can reduce steroid frequency over time, but this should be done under medical supervision.
• Topical calcineurin inhibitors (tacrolimus, pimecrolimus): No known interaction. These can be applied after RLT sessions.
• Antihistamines: No interaction. Continue as directed.
• Dupilumab (Dupixent): No contraindication, though patients on biologics should inform their dermatologist about any adjunctive treatments.

Frequently Asked Questions

Can red light therapy cure eczema?

No. Eczema is a chronic condition with genetic and environmental components. Red light therapy may help manage symptoms, reduce flare severity, and support barrier repair, but it does not address the underlying genetic predisposition.

Is it safe for children?

The evidence suggests red light therapy is safe for children, and several studies have included paediatric participants. Use shorter sessions (5-8 minutes initially) and supervise the child throughout. Ensure eye protection is worn.

How quickly will I see results?

Most people notice reduced itching within 2-3 weeks of consistent use. Visible skin improvements typically appear between weeks 4 and 8. Give any protocol at least 8-12 weeks before deciding whether it is effective for you.

Can I use it during a flare?

Yes. In fact, early intervention during a flare may help reduce its severity and duration. However, if the flare involves broken, weeping, or infected skin, focus on treating the acute phase with your prescribed medication first.

Does skin colour affect the results?

Melanin absorbs some red and NIR light, which means darker skin may require slightly longer treatment times or closer positioning. However, unlike UV phototherapy, there is no increased risk of hyperpigmentation or burns with red and NIR wavelengths.

The Bottom Line

The evidence for red light therapy in eczema management is promising but still developing. The anti-inflammatory, barrier-repair, and mast-cell-stabilising effects are well documented at a cellular level, and early clinical studies show meaningful improvements in symptom scores. For people dealing with chronic eczema who want to reduce their reliance on topical steroids, red light therapy represents a safe, non-invasive option worth discussing with their dermatologist.

The most important factors for success are consistent use (at least 3-5 times per week), appropriate wavelengths (630-660 nm and 810-850 nm), adequate dosing (10-30 J/cm2 per session), and realistic expectations. Eczema management is a marathon, not a sprint, and red light therapy is best understood as one tool in a broader strategy that includes barrier protection, trigger avoidance, and appropriate medical treatment.

---

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before starting any new treatment for eczema or dermatitis.